First therapy to be FDA-approved and EC-authorized for acquired hypothalamic obesity ---- European Commission grants authorization in adults and children 4 years of age and abo ...
FDA approval establishes setmelanotide as the first labeled option for acquired hypothalamic obesity, addressing a population estimated at ~10,000 in the US and characterized by severe hyperphagia.
The hypothalamus integrates neurohormonal signaling from gut and adipose tissue. Specific hypothalamic nuclei, including the dorsomedial nucleus (DMN), paraventricular nucleus (PVN) and ventromedial ...
Hypothalamic obesity (HyOb) develops when damage to the hypothalamus — from brain tumors, traumatic brain injury, radiation therapy, or stroke — disrupts how your body regulates appetite and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results